ClinicalTrials.gg
RecruitingNCT07744763Updated Aug 4, 2026

A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of SYS6041 in Advanced Solid Tumors, sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Mar 2025, registered Jul 2026).
  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This trial is the first-in-human study of SYS6041, a multicenter, open-label, dose-escalation, dose-reassignment and cohort-expansion Phase I/IIa clinical study, which aims to evaluate the safety, tolerability, pharmacokinetic (PK) profile and preliminary antitumor efficacy of SYS6041 in participants with advanced solid tumors.

Read the detailed description

The trial consists of four stages: Phase I dose-escalation stage, as well as Phase IIa dose-reassignment stage, dose-expansion stage and cohort-expansion stage.

The dose-escalation stage includes a screening period (28 days), a treatment period (DLT observation period and subsequent treatment period), and a follow-up period (safety follow-up and survival follow-up). The first cycle (21 days) in which participants receive SYS6041 administration is defined as the DLT observation period.

Based on data obtained from the dose-escalation and dose-reassignment stages, two dose levels will be selected for randomized enrollment in the dose-expansion stage to further assess the efficacy, safety and pharmacokinetic (PK) profile of candidate doses and confirm the recommended Phase 2 dose (RP2D).

The cohort-expansion stage comprises a screening period (28 days), a treatment period and a follow-up period (safety follow-up and survival follow-up). Eligible screened participants will receive intravenous infusion of SYS6041 on Day 1 of each cycle, with each treatment cycle lasting 3 weeks. Treatment will be discontinued upon the first occurrence of progressive disease (PD), intolerable toxicity, withdrawal of informed consent, loss to follow-up, death, or any other conditions meeting the treatment discontinuation criteria.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd. is the lead sponsor of 42 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged >= 18 years.
  2. The expected survival time is >=3 months.
  3. (ECOG) 0\~1.
  4. Willing to provide recent tumor tissue specimens for FRα testing.
  5. At least one as defined by Version 1.1.
  6. The organ function level and related laboratory indicators must meet requirement.
  7. Additional inclusion criteria for the dose-escalation stage: or cytologically confirmed unresectable locally advanced or ovarian cancer, endometrial cancer, NSCLC, or breast cancer with disease progression following standard therapy.
  8. Additional inclusion criteria for the expansion cohort stage: Radiological and/or pathological progression or intolerance to the most recent systemic anti-tumor therapy.
  9. Additional inclusion criteria for the expansion cohort stage: Histologically or cytologically confirmed advanced solid tumors, including ovarian cancer, endometrial cancer, or other FRα-positive solid tumors that have received at least one .
  10. Agree to use reliable and effective methods of during the study treatment period and for at least 5 months (for male subjects) or 8 months (for female subjects) after the last study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Known severe allergic reaction to the study drug or any other components/ in the formulation.
  2. Untreated (including those identified at baseline screening) or unstable parenchymal , spinal or spinal cord compression, carcinomatous meningitis.
  3. History of other malignant tumors within 3 years, or concurrent active malignant tumors.
  4. Prior treatment with ADCs carrying topoisomerase I inhibitor payloads.
  5. Adverse reactions from prior anti-tumor therapies have not recovered to Grade ≤1 per v5.0.
  6. Received immunotherapy, macromolecular targeted therapy or other anti-tumor biotherapy within 4 weeks prior to the first dose; or received endocrine therapy, cytotoxic chemotherapy, small-molecule targeted therapy within 2 weeks prior to the first dose; or received traditional Chinese medicinal preparations with anti-tumor indications within 2 weeks prior to the first dose.
  7. Patients who have undergone major organ surgery within 28 days prior to the first dose, or have planned systemic or local tumor resection during the study period.
  8. Patients who have received strong inhibitors or strong CYP3A4 inducers systemically within 14 days prior to the first dose, or require continuous systemic administration of such agents during study treatment.
  9. Severe chronic or active infections requiring intravenous antibacterial, antifungal or antiviral therapy within 14 days prior to the first dose (including tuberculous infection, etc.).
  10. Subjects receiving long-term therapy (e.g., cyclosporine) or daily systemic therapy.
  11. Uncontrolled serous cavity effusions requiring frequent drainage or medical intervention within 7 days prior to the first dose.
  12. Presence of risk factors for intestinal obstruction or intestinal perforation.
  13. Grade ≥2 severe diarrhea per CTCAE within 7 days prior to the first dose.
  14. History of non-infectious lung disease/pneumonitis requiring steroid therapy, or current interstitial lung disease/pneumonitis, or suspected such diseases identified by imaging examinations during screening.
  15. History of severe cardiovascular diseases.
  16. Female subjects who are pregnant or breastfeeding.
  17. Any other circumstances that may interfere with the subject's participation in study procedures, compromise the subject's maximum benefit from study participation, or affect study results, in the Investigator's judgment.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    SYS6041

    intravenous injection

    Drug: SYS6041

Interventions

  • DrugSYS6041

    Farletuzumab-exatecan antibody-drug conjugate targeting human FRα

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity (DLT)

    Incidence of DLT (Applicable only to the Phase I dose-escalation stage)

    Time frame: 21 days

  2. ORR

    ORR assessed by investigators per RECIST 1.1

    Time frame: Through study completion,up to 2 years.

Secondary outcomes

  1. Number of participants with Adverse events (AEs)

    Safety assessments

    Time frame: Up to 2 years

  2. DCR

    During follow-up

    Time frame: Up to 2 years

  3. Progression-free survival(PFS)

    During follow-up

    Time frame: Up to 2 years

  4. Overall survival (OS)

    During follow-up

    Time frame: Up to 2 years

  5. PK parameters

    Time to maximum observed concentration(T-max)

    Time frame: Up to 2 years

  6. Immunogenicity

    Incidence of anti-drug antibodies (ADA)

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
  • Xiaohua
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2026
First posted
Aug 4, 2026
StartActual
Mar 28, 2025
Primary completionEst.
Mar 28, 2027
CompletionEst.
Mar 31, 2027
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07744763
Responsible party
Sponsor
First posted
Aug 4, 2026
Start date
Mar 28, 2025
Primary completion
Mar 28, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Aug 4, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
031169085587

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion